Potential benefit of 1-a-cholecalciferol in hypomagnesaemia induced by cyclosporin
The association between cyclosporin neurotoxicity and hypomagnesaemia in allogeneic bone marrow recipients was reported in 1984.' Despite lowered serum magnesium concentrations, urinary excretion of magnesium remains inappropriately high, an effect assumed to be due to a defect in renal tubular reabsorption ofmagnesium as a result of taking cyclosporin. Treatment with oral or parenteral magnesium is usually successful, but large doses of oral magnesium salts are often poorly tolerated because of diarrhoea. Reduction of renal magnesium excretion using amiloride may be helpful, but the combination of this drug with cyclosporin may give rise to hyperkalaemia. In this report we describe a patient with persistent symptomatic hypomagnesaemia after treatment with cyclosporin A who was given 1 -acholecalciferol with subsequent correction of the serum magnesium concentration.
Case report A 44 year old woman with acute myelomonocytic (M4) leukaemia in second remission received an allogeneic bone marrow transplant and prophylaxis with cyclosporin A. Graft-versus-host disease ensued with typical skin manifestations and diarrhoea. High dose prednisolone was given and cyclosporin A continued. Paraesthesiae and muscle cramps developed, and both the serum magnesium and calcium were subnormal at 0 33 mmol/l and 1 3 mmol/l, respectively, the serum albumin concentration being 35 g/l. Chvostek's and Trousseau's signs were positive, and intravenous magnesium and calcium replacement was begun. Subsequently oral magnesium was given in the form of Maalox, but doses above 20 mmol/day worsened the diarrhoea. Despite several infusions ofmagnesium (25-50 mmol/ day), the serum magnesium concentration repeatedly fell below the reference range and paraesthesiae recurred. Urinary magnesium excretion remained inappropriately high (figure), and amiloride, 5 mg twice a day, was given but had to be withdrawn because of hyperkalaemia. The serum concentration of 1,25 dihydroxycholecalciferol was subnormal at 10 pg/ml (reference range 18-66 pg/ml), and in an attempt to increase gastrointestinal absorption, and possibly renal tubular reabsorption ofmagnesium, 1 -a-cholecalciferol 250 ng/day was begun. The serum mag- group.bmj.com on August 28, 2017 -Published by http://jcp.bmj.com/ Downloaded from nesium subsequently stabilised at the lower end of the reference range (figure), and no further intravenous magnesium replacement was required.
Comment
Calcium and magnesium share a transport system in the gut, and both 1-a-hydroxycholecalciferol and 1,25 dihydroxycholecalciferol have been successfully used in the treatment of hypomagnesaemia associated with the short bowel syndrome.2 A recent report describes the use of l-a-cholecalciferol in a patient with the short bowel syndrome in whom, the authors claim, renal tubular absorption of magnesium was increased. 3 In our case oral magnesium supplements in high doses were associated with diarrhoea, and I-a-hydroxycholecalciferol enhanced magnesium absorption and possibly reduced urinary losses. The figure shows that normal serum magnesium concentrations were maintained after the administration of 1-acholecalciferol, with resolution of symptoms. Two 24 hour collections obtained while the patient was taking 1-a-cholecalciferol contained 5 and 8 mmol magnesium (figure), suggesting that any effect of 1-a-cholecalciferol on renal magnesium conservation was minimal.
The role of vitamin D in the renal handling of magnesium is unclear. Levine et al found a diminution of magnesium tubular reabsorption in vitamin D deficient rats given 1,25 dihydroxycholecalciferol,4 and Burnatowska et al showed an increased fractional excretion of magnesium in hamsters from which thyroid and parathyroid glands had been removed.' Fukumoto et al, however, described a decrease in fractional excretion of magnesium in a hypomagnesaemic patient with the short bowel syndrome who was given large doses of I-a-cholecalciferol. 3 In their patient, as in our case, the serum concentration of 1,25 dihydroxy-cholecalciferol was abnormally low, and this was felt to contribute to impaired renal resorption of magnesium.
More work is required on the effect of 1-acholecalciferol on renal magnesium handling, but the case reported here suggests that this drug may be useful in the management of hypomagnesaemia induced by cyclosporin. Hypercalcaemia is associated with ovarian carcinoma frequently enough for the ovary not to be ignored as a primary tumour site in women presenting with clinically unexplainable hypercalcaemia.' We therefore felt it would be of interest to examine a number of ovarian carcinomas for the presence of PTHrP.
Immunocytochemistry was performed using an antibody raised against the first 34 amino acids of PTHrP (kindly donated by Drs GV Segre and H Juppner, Boston, Massachusetts, USA) and standard indirect immunocytochemical techniques. Two cases of ovarian carcinoma associated with hypercalcaemia (one small cell and one non-small cell type, supplied by Dr GR Dickersin, Boston) were found to contain PTHrP. PTHrP was present throughout the cytoplasm of the tumour cells but was absent from inflammatory and stromal cells and areas of tumour necrosis. The immunoreactivity was completely abolished when the antibody was pre-incubated with PTHrP (1-34) ovemight. Two cases of serous cystadenocarcinoma and two cases of mucinous cystadenocarcinoma of the ovary (from patients who were normocalcaemic) were found to be negative for PTHrP.
Normal adult ovary does not produce PTHrP, but the peptide has been detected in the human fetal gonad.4 This is the first report of the presence ofPTHrP in a hypercalcaemic ovarian carcinoma. While the pathophysiological role of PTHrP is yet to be elucidated, one possibility is that in addition to it inducing hypercalcaemia it may stimulate the growth of tumours in an autocrine manner.' It may also regulate the fetal calcium balance. 4 The presumably, secreted into the fluid.3 As only very low concentrations of active renin are found in the ovary, it has been postulated that ovarian prorenin may be biologically active without any necessity for prior removal of the propart sequence.' The role of ovarian prorenin is still unclear but it probably operates through the formation of angiotensin II (AII). Studies with the AII antagonist, saralasin, have indicated a direct role for AII in ovulation,4 and, in addition to its effects on steroidogenesis, the vasoconstrictor and angiogenic properties may be important for follicular growth.
Cysts are commonly derived from the ovarian follicles and frequently contain a large volume of liquid. It was thus considered of interest to determine whether this fluid might also contain a high concentration of prorenin. The fluid from six ovarian cysts removed at laparotomy was collected, stored at -20°C, and assayed for prorenin by the trypsin-activation method of McIntyre et al.' Renin activity was estimated by measuring the rate of angiotensin I (AI) production from human angiotensinogen.6
Prorenin was detected in the fluid from four of the cysts assayed-three of follicular origin and one from a mucinous cystadenoma-with two others being virtually negative (table) . The concentration of active renin detected in all of the fluids was very low (less than 5 0 of total) and may have been due to partial activation of the prorenin during collection. This predominance of prorenin over renin is in keeping with previous results for normal ovarian follicular fluid. ' 
